

# C Jerjes-Sánchez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8723538/publications.pdf>

Version: 2024-02-01

68  
papers

1,581  
citations

586496

16  
h-index

340414

39  
g-index

81  
all docs

81  
docs citations

81  
times ranked

1807  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2022, 193, 106744.	1.3	8
2	Unexpected arterial thrombosis and acute limb ischemia in COVID-19 patients. Results from the Ibero-Latin American acute arterial thrombosis registry in COVID-19: (ARTICO-19). <i>Vascular</i> , 2022, 30, 1107-1114.	0.4	5
3	Riociguat in the Treatment of Pulmonary Arterial Hypertension in Mexico. <i>Archives of Medical Research</i> , 2022, , .	1.5	1
4	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. <i>Future Cardiology</i> , 2021, 17, 19-38.	0.5	19
5	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.	0.7	16
6	Clinical outcomes of very elderly patients treated with ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 260-271.	1.0	2
7	In silico evidence of cardiac troponin nonclassical secretion: new insights on the pathobiology of myocardial injury. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
8	Resveratrol Prevents Right Ventricle Dysfunction, Calcium Mishandling, and Energetic Failure via SIRT3 Stimulation in Pulmonary Arterial Hypertension. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	1.9	16
9	Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening. <i>American Journal of Medicine</i> , 2021, 134, 893-901.e11.	0.6	31
10	Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-21.	1.9	5
11	Differences between surviving and non-surviving venous thromboembolism COVID-19 patients: a systematic review. <i>Thrombosis Journal</i> , 2021, 19, 101.	0.9	4
12	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 707-717.	2.5	89
13	Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-17.	1.9	15
14	Resveratrol Prevents Right Ventricle Remodeling and Dysfunction in Monocrotaline-Induced Pulmonary Arterial Hypertension with a Limited Improvement in the Lung Vasculature. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-13.	1.9	21
15	Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 929-941.	1.0	18
16	Systemic thrombolysis and anticoagulation improved biomarker measurements in massive-like pulmonary embolism and severe COVID-19 pneumonia: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-8.	0.3	3
17	Explaining the increment in coronary heart disease mortality in Mexico between 2000 and 2012. <i>PLoS ONE</i> , 2020, 15, e0242930.	1.1	3
18	Suspected Cardiovascular Syncope in the AER. , 2019, , 31-42.		0

#	ARTICLE	IF	CITATIONS
19	Optimizing the Use of Biomarkers in the AER. , 2019, , 43-71.		0
20	Cardiac Tamponade in the AER. , 2019, , 125-138.		0
21	Dyspnea in the AER. , 2019, , 15-30.		0
22	Acute Left Heart Failure in the AER. , 2019, , 225-246.		0
23	Tachyarrhythmias in the AER. , 2019, , 187-208.		0
24	Cardiac Arrest in the AER. , 2019, , 247-257.		0
25	Pacemaker Emergencies in the AER. , 2019, , 271-305.		0
26	Cardiology Bedside Interventions in the AER. , 2019, , 307-319.		0
27	Acute Coronary Syndromes in the AER. , 2019, , 73-99.		2
28	Pulmonary Embolism in the AER. , 2019, , 153-177.		0
29	Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. Clinical Cardiology, 2019, 42, 553-560.	0.7	16
30	Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFer-RITU2: study protocol. BMJ Open, 2019, 9, e022826.	0.8	14
31	Cardiogenic Shock in the AER. , 2019, , 139-151.		0
32	Chest Pain in the AER. , 2019, , 1-14.		0
33	B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women: a prospective, multicentre, cross-sectional study. BMJ Open, 2018, 8, e022562.	0.8	8
34	Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism. American Journal of Emergency Medicine, 2018, 36, 1925.e3-1925.e4.	0.7	2
35	Giant coronary ectasia and athlete's heart mimicking an acute coronary syndrome. Archivos De Cardiologia De Mexico, 2018, 88, 228-229.	0.1	0
36	The use of cardiac CT as a roadmap for resolving coronary stent dislodgement. Archivos De Cardiologia De Mexico, 2018, 88, 318-319.	0.1	1

#	ARTICLE	IF	CITATIONS
37	Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 377-385.	1.0	114
38	Mexican registry of pulmonary hypertension. <i>Archivos De Cardiologia De Mexico</i> , 2017, 87, 13-17.	0.1	3
39	Inferior vena cava filters in pulmonary embolism: A historic controversy. <i>Archivos De Cardiologia De Mexico</i> , 2017, 87, 155-166.	0.1	7
40	Ischaemic stroke from a large mitral vegetation as clinical presentation of infective endocarditis. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 522-522.	0.5	2
41	Intermediate- to high-risk pulmonary embolism with normal B-type natriuretic peptide. <i>American Journal of Emergency Medicine</i> , 2016, 34, 2463.e1-2463.e3.	0.7	4
42	Clinical management and hospital outcomes of acute coronary syndrome patients in Mexico: The Third National Registry of Acute Coronary Syndromes (RENASICA III). <i>Archivos De Cardiologia De Mexico</i> , 2016, 86, 221-232.	0.1	17
43	The Role of a Multimodality Imaging Approach in Diagnosis and Stratification of Aborted Sudden Cardiac Death. <i>Canadian Journal of Cardiology</i> , 2015, 31, 103.e9-103.e11.	0.8	1
44	Pharmacokinetics and Pharmacodynamics of Fibrinolytic Agents. , 2015, , 19-39.		1
45	Patients for Thrombolysis. , 2015, , 107-130.		5
46	Current Guidelines and Recommendations for Thrombolysis Use in Pulmonary Embolism. , 2015, , 151-174.		1
47	Thrombolysis in Pulmonary Embolism. , 2015, , 175-210.		5
48	Third national registry of acute coronary syndromes (RENASICA III). <i>Archivos De Cardiologia De Mexico</i> , 2015, 85, 207-214.	0.1	12
49	Anticoagulation as Adjunctive Treatment and One-Hour Alteplase Infusion. , 2015, , 131-149.		0
50	Thrombolysis in Special Situations. , 2015, , 211-227.		0
51	Mechanisms of Thrombosis. , 2015, , 1-17.		5
52	Myopericarditis with predominantly right ventricular involvement with normal B-type natriuretic peptide and cardiac tamponade as the initial manifestation of systemic lupus erythematosus. <i>Lupus</i> , 2014, 23, 935-938.	0.8	8
53	Stress Transient Hypertrophic Cardiomyopathy and B-Type Natriuretic Peptide Role. <i>Pediatric Cardiology</i> , 2013, 34, 702-706.	0.6	1
54	Risk Factors, Therapeutic Approaches, and In-Hospital Outcomes in Mexicans With ST-Elevation Acute Myocardial Infarction: The RENASICA II Multicenter Registry. <i>Clinical Cardiology</i> , 2013, 36, 241-248.	0.7	20

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 624-633.	1.6	291
56	Safety and efficacy of sitaxsentan 50 and 100Âmg in patients with pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 33-39.	1.1	32
57	FREEDOM-M: Efficacy and Safety of Oral Treprostinil Diethanolamine as Monotherapy in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 140, 1044A.	0.4	6
58	Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 154-162.	1.0	21
59	Fibrinolytic therapy in left side-prosthetic valve acute thrombosis. In depth systematic review. <i>Archivos De Cardiologia De Mexico</i> , 2008, 78, 309-17.	0.1	11
60	Venous and arterial thrombosis: a continuous spectrum of the same disease?. <i>European Heart Journal</i> , 2005, 26, 3-4.	1.0	73
61	Mexican Registry of Acute Coronary Syndromes. <i>Archivos De Cardiologia De Mexico</i> , 2005, 75 Suppl 1, S6-32.	0.1	8
62	High dose and short-term streptokinase infusion in patients with pulmonary embolism: prospective with seven-year follow-up trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 237-247.	1.0	26
63	The Dressler Syndrome After Pulmonary Embolism. <i>American Journal of Cardiology</i> , 1996, 78, 343-345.	0.7	17
64	Intrapleural Fibrinolysis With Streptokinase as an Adjunctive Treatment in Hemothorax and Empyema. <i>Chest</i> , 1996, 109, 1514-1519.	0.4	151
65	Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 1995, 2, 227-229.	1.0	393
66	Short-term efficacy and safety of a single five-milligram dose of oral nifedipine in uncontrolled essential systemic hypertension. <i>American Journal of Cardiology</i> , 1991, 68, 123-125.	0.7	2
67	Single-Dose Sublingual Nifedipine as the Only Treatment in Hypertensive Urgencies and Emergencies. <i>Angiology</i> , 1991, 42, 908-913.	0.8	13
68	Dressler-like Syndrome After Pulmonary Embolism and Infarction. <i>Chest</i> , 1987, 92, 115-117.	0.4	18